Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection

다국어 초록 (Multilingual Abstract)

Background: Infections by Carbapenem-Resistant Enterobacteriaceae (CRE) remain a leading cause of death in critically ill patients. Fosfomycin has been regarded as an alternative therapy for treatment of infections caused by CRE organisms. The purpose of this study is to evaluate clinical outcomes amongst patients with CRE infection who are receiving a fosfomycin dosing regimen using a Monte Carlo simulation and fosfomycin minimum inhibitory concentration (MIC).
Materials and Methods: Fosfomycin MIC was defined by the E-test method. We used Fosfomycin pharmacokinetic parameters from a previously published study. The percent of the time period in which the drug concentration exceeded the MIC, or %T>MIC, used in this study were determined to be 70% of T>MIC and 100% of T>MIC, respectively. All dosing regimens were estimated for the probability of target attainment using a Monte Carlo simulation.
Results: In this study, we found the MIC's of fosfomycin against CRE isolates ranged from 8 mg/L to 96 mg/L. The total daily dose of fosfomycin ranged from 16 - 24 g and was administered utilizing various fosfomycin dosing regimens to achieve the pharmacokinetic/ pharmacodynamic (PK/PD) target in pathogens with a MIC of 32 mg/L for 70%T>MIC and a MIC of 12 mg/L for 100%T>MIC, respectively. For the twelve patients who received the recommended fosfomycin dosing regimen, eleven achieved bacterial eradication for a microbiological cure rate of 91%; and of those patients achieving eradication, two died despite having negative cultures for CRE; the one remaining patient had bacterial persistence. The most commonly observed adverse drug reactions were hypernatremia (3 cases) and hypokalemia (3 cases) and acute kidney injury (3 cases).
Conclusion: Our findings suggest fosfomycin has tended to good efficacy when using dosing regimens that achieve the PK/PD target. Nonetheless, further validation of these regimens in larger populations is needed.

참고문헌 (Reference)

1 Prawang A, "Treatment and clinical outcome of Colistin-resistant Klebsiella pneumoniae bacteremia patients" 51 : 263-269, 2020

2 The National Antimicrobial Resistance Surveillance Thailand (NARST), "The situation of antimicrobial resistance in health service areas from January to June 2019"

3 Michalopoulos AS, "The revival of fosfomycin" 15 : e732-e739, 2011

4 Al-aloul M, "The renoprotective effect of concomitant fosfomycin in the treatment of pulmonary exacerbations in cystic fibrosis" 12 : 652-658, 2019

5 Santimaleeworagun W, "The prevalence of colistin-resistant Gram-negative bacteria isolated from hospitalized patients with bacteremia" 10 : 56-59, 2020

6 Tseng SP, "The plasmid-mediated fosfomycin resistance determinants and synergy of fosfomycin and meropenem in carbapenem-resistant Klebsiella pneumoniae isolates in Taiwan" 50 : 653-661, 2017

7 Joukhadar C, "Target site penetration of fosfomycin in critically ill patients" 51 : 1247-1252, 2003

8 Bakthavatchalam YD, "Synergistic activity of fosfomycin–meropenem and fosfomycin–colistin against carbapenem resistant Klebsiella pneumoniae: an in vitro evidence" 6 : FSO461-, 2020

9 Wang J, "Synergistic activity of colistin/fosfomycin combination against carbapenemase-producing Klebsiella pneumoniae in an in vitro pharmacokinetic/pharmacodynamic model" 2018 : 5720417-, 2018

10 Rhodes A, "Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016" 43 : 304-377, 2017

11 Ting SW, "Risk factors and outcomes for the acquisition of carbapenem-resistant Gramnegative bacillus bacteremia : A retrospective propensity-matched case control study" 51 : 621-628, 2018

12 Bradley JS, "Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation" 22 : 982-985, 2003

13 Tamma PD, "Phenotypic detection of carbapenemase-producing organisms from clinical isolates" 56 : e01140-e01218, 2018

14 Scaglione F, "Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit : setting appropriate dosing regimens" 32 : 294-301, 2008

15 Fransen F, "Pharmacodynamics of fosfomycin against ESBL-and/or carbapenemase-producing Enterobacteriaceae" 72 : 3374-3381, 2017

16 Docobo-Pérez F, "Pharmacodynamics of fosfomycin : insights into clinical use for antimicrobial resistance" 59 : 5602-5610, 2015

17 Albiero J, "Pharmacodynamic evaluation of the potential clinical utility of fosfomycin and meropenem in combination therapy against KPC-2-producing Klebsiella pneumoniae" 60 : 4128-4139, 2016

18 López-Montesinos I, "Oral and intravenous fosfomycin in complicated urinary tract infections" 32 (32): 37-44, 2019

19 Asuphon O, "Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic(PK/PD)simulation" 50 : 23-29, 2016

20 Santimaleeworagun W, "Optimization of fosfomycin doses for treating Pseudomonas aeruginosa infection in critically ill patients by using Monte Carlo simulation" 11 : 870-878, 2019

21 Roberts JA, "Monte Carlo simulations : maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients" 66 : 227-231, 2011

22 Khwaja A, "KDIGO clinical practice guidelines for acute kidney injury" 120 : 179-184, 2012

23 Shorr AF, "Intravenous fosfomycin for the treatment of hospitalized patients with serious infections" 15 : 935-945, 2017

24 Sheu CC, "Infections caused by carbapenem-resistant Enterobacteriaceae : An update on therapeutic options" 10 : 1-13, 2019

25 Lepak AJ, "In vivo pharmacokinetics and pharmacodynamics of ZTI-01(Fosfomycin for injection)in the neutropenic murine thigh infection model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa" 61 : 1-11, 2017

26 Prawang A, "In vitro antibiotic synergy colistin-resistant Klebsiella pneumoniae" 50 : 703-707, 2019

27 Kaye KS, "Fosfomycin for injection(ZTI-01)versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis : ZEUS, a phase 2/3 randomized trial" 69 : 2045-2056, 2019

28 Silver LL, "Fosfomycin : Mechanism and resistance" 7 : 1-11, 2017

29 Falagas ME, "Fosfomycin" 29 : 321-347, 2016

30 Matzi V, "Extracellular concentrations of fosfomycin in lung tissue of septic patients" 65 : 995-998, 2010

31 VanScoy BD, "Exploration of the pharmacokinetic-pharmacodynamic relationships for fosfomycin efficacy using an in Vitro infection model" 59 : 7170-7177, 2015

32 Rodríguez-Gascón A, "Deciphering pharmacokinetics and pharmacodynamics of fosfomycin" 32 (32): 19-24, 2019

33 De Rosa FG, "Critical issues for Klebsiella pneumoniae KPCcarbapenemase producing K. pneumoniae infections : a critical agenda" 10 : 283-294, 2015

34 Roussos N, "Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections" 34 : 506-515, 2009

35 European Committee on Antimicrobial Susceptibility Testing (EUCAST), "Clinical breakpoints -breakpoints and guidance"

36 Codjoe FS, "Carbapenem resistance: a review" 6 : 1-, 2017

37 Yaita K, "Biofilm-forming by carbapenem resistant enterobacteriaceae may contribute to the blood stream infection" 20 : 5954-, 2019

38 Bilbao-Meseguer I, "Augmented renal clearance in critically ill patients : a systematic review" 57 : 1107-1121, 2018

39 Mahmoud SH, "Augmented renal clearance in critical illness : An important consideration in drug dosing" 9 : 1-27, 2017

40 Florent A, "Adverse events associated with intravenous fosfomycin" 37 : 82-83, 2011

41 Ordooei Javan A, "A review on colistin nephrotoxicity" 71 : 801-810, 2015